AR and pachyonychia congenita: Therefore, systemic therapies for advanced PC include endocrine therapies that prevent testicular androgen production, the CYP17A1 inhibitor abiraterone that prevents systemic androgen synthesis, and high-affinity competitive AR antagonists such as enzalutamide, apalutamide, and darolutamide (1–5).